Cancer vaccine trial for colorectal cancer halted after just one patient

NCT ID NCT05350501

Terminated Disease control Sponsor: Enterome Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of a therapeutic vaccine (EO2040) and an immunotherapy drug (nivolumab) in colorectal cancer patients who had minimal residual disease detected by a blood test after completing standard treatment. The goal was to clear remaining cancer cells and prevent recurrence. However, the study was terminated early after enrolling only one participant, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EO2040 (a therapeutic peptide vaccine) combined with nivolumab (an immunotherapy drug)
What this could lead to: If successful, this approach could help eliminate remaining cancer cells in colorectal cancer patients after standard treatment, potentially reducing the risk of recurrence.
What could go wrong: The trial was terminated early with only 1 participant, so no meaningful conclusions can be drawn. The combination may cause immune-related side effects, and its effectiveness is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

MD Anderson

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.